<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03855891</url>
  </required_header>
  <id_info>
    <org_study_id>1741909-2019</org_study_id>
    <nct_id>NCT03855891</nct_id>
  </id_info>
  <brief_title>Micro-RNA Profile in Patients With Different Stages of Atherosclerosis According to CTA</brief_title>
  <acronym>CT-CA-miRNA</acronym>
  <official_title>Evaluation of the Circulating Micro-RNA Profile Specificity in Patients With Different Stages of Atherosclerosis According to MSCT Coronary Angiography</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>I.M. Sechenov First Moscow State Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>I.M. Sechenov First Moscow State Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this single-center study is to determine the spectrum and levels of&#xD;
      cardiospecific circulating microRNAs in patients with different stages of atherosclerosis&#xD;
      according to 640-slice multispiral computed tomography (MSCT).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be conducted in two phases. Phase one. After signing the informed consent,&#xD;
      patients with coronary heart disease, angina pectoris II-IV functional class, who underwent&#xD;
      MSCT angiography of the coronary arteries for medical reasons, regulated in the relevant ESC&#xD;
      and the Russian Society of Cardiology guidelines, will be included in the study. According to&#xD;
      the results of MSCT, the participants will be divided into 4 groups: those with&#xD;
      atherosclerotic plaques with signs of instability; those with stable atherosclerotic plaques&#xD;
      without marked calcification; those with calcined atherosclerotic plaques; those with no&#xD;
      signs of atherosclerosis of the coronary arteries. Plasma samples will be analyzed by&#xD;
      microarray, using a cardiospecific set.&#xD;
&#xD;
      Phase two. Validation of the results obtained after the first phase will be performed on a&#xD;
      larger sample of patients. Patients after signing an informed consent will also undergo MSCT&#xD;
      angiography of coronary arteries and according to its results will be devided in 4 groups. To&#xD;
      assess the level of microRNA expression in the blood of patients, real-time reverse&#xD;
      transcription-polymerase chain reaction (RT-PCR) will be used.&#xD;
&#xD;
      The expected result of the study. For the first time ever, there will be determined the&#xD;
      profile of circulating regulatory RNA in patients who underwent MSCT angiography of coronary&#xD;
      arteries. Features of expression of circulating microRNAs will be compared with different&#xD;
      severity degrees of the atherosclerotic process based on MSCT criteria. The results will be&#xD;
      compared with each other (including the &quot;control&quot; group), which will allow to identify common&#xD;
      patterns and specific differences.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2019</start_date>
  <completion_date type="Actual">October 1, 2020</completion_date>
  <primary_completion_date type="Actual">August 14, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determination of the profile of circulating microRNAs in patients with different degrees of severity of atherosclerotic process on the MSCT criteria basis.</measure>
    <time_frame>2 days</time_frame>
    <description>Analysis of the spectrum and levels of cardiospecific circulating microRNAs in patients with different degrees of severity of atherosclerotic process on the MSCT criteria basis.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">81</enrollment>
  <condition>Ischemic Heart Disease</condition>
  <condition>Atherosclerosis</condition>
  <arm_group>
    <arm_group_label>Study group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A group of patients with blood tests</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>blood test</intervention_name>
    <description>Blood test for spectrum and level of cardiospecific micro-RNA</description>
    <arm_group_label>Study group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent of the patient to participate in the study;&#xD;
&#xD;
          -  Age 18-80;&#xD;
&#xD;
          -  The presence of medical indications for MSCT angiography of coronary arteries in&#xD;
             connection with suspected coronary heart disease.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age less than 18 or more than 80;&#xD;
&#xD;
          -  Pregnancy, breast-feeding;&#xD;
&#xD;
          -  Patients who have not undergone (and do not plan) MSCT coronary angiography;&#xD;
&#xD;
          -  Any surgical intervention on the heart in history;&#xD;
&#xD;
          -  Severe heart failure (III-IV NYHA classes);&#xD;
&#xD;
          -  History of myocardial infarction;&#xD;
&#xD;
          -  The body mass index of 35 or more;&#xD;
&#xD;
          -  More than twice the ALT and/or AST level;&#xD;
&#xD;
          -  The presence of severe somatic pathology (except coronary atherosclerosis);&#xD;
&#xD;
          -  Patient's refusal to participate in the study;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philipp Kopylov, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sechenov Univercity</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>IMSechenovMMA</name>
      <address>
        <city>Moscow</city>
        <zip>119991</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>February 25, 2019</study_first_submitted>
  <study_first_submitted_qc>February 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 27, 2019</study_first_posted>
  <last_update_submitted>December 19, 2020</last_update_submitted>
  <last_update_submitted_qc>December 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>I.M. Sechenov First Moscow State Medical University</investigator_affiliation>
    <investigator_full_name>Andrei N Rozhkov, MD</investigator_full_name>
    <investigator_title>Post-graduate student of Department of of Preventive and Emergency Cardiology I.M. Sechenov First Moscow State Medical University</investigator_title>
  </responsible_party>
  <keyword>Ischemic Heart Disease</keyword>
  <keyword>Atherosclerosis</keyword>
  <keyword>micro-RNA</keyword>
  <keyword>multislice spiral computed tomography</keyword>
  <keyword>coronary angiography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Data disclosure is not permitted by the local ethics committee. For more information about the study, you need to contact the principal investigator.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

